1. Generics Bulletin

Amgen Rivals Teva With Rituximab Approved For RA

US Market Composed Of Three Biosimilars Plus Rituxan

 
• By Dean Rudge

Amgen has added a further treatment for inflammatory diseases to its vast portfolio, with the FDA approving its rituximab biosimilar Riabni for rheumatoid arthritis.

Approved
Two of three biosimilars now have the RA indication • Source: Shutterstock: PSNPJua

Teva’s commercial advantage from being the sole rituximab biosimilar sponsor with a rheumatoid arthritis indication has been blunted. Amgen’s Riabni (rituximab-arrx) has been approved for the same inflammatory joint disease indication by the US Food and Drug Administration.

Already approved for the treatment of adult patients with non-Hodgkin’s lymphoma, chronic lymphocytic leukemia, Wegener’s granulomatosis and microscopic polyangiitis, Riabni’s approval for moderate to severely active rheumatoid arthritis means

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Products

More from Generics Bulletin

After Jazz, Hikma Agrees $50m Settlement For ‘Most’ Xyrem ‘Pay-For-Delay’ Claims

 
• By Dean Rudge

Hikma said it would admit no wrongdoing or liability after reaching a preliminary settlement agreement over illicit ‘pay-for-delay’ claims involving its US version of Xyrem “that protects the company’s interests and provides clarity to our stakeholders.”

CIOMS Welcomes Draft Report Feedback On The Inevitable Future Of AI In Pharmacovigilance

 
• By Urtė Fultinavičiūtė

Pharmacovigilance is a perfect rule-based and manual work-intensive playground for experimenting with AI. While some off-patent drug firms are already exploring new automation tools, regulation is lagging behind, leaving a gap for uncertainty.

Viatris Pens Aprepitant Settlement Agreement After Kabi Loses Initial Patent Case

 
• By Dean Rudge

Viatris will look to introduce generic versions of Heron Therapeutics’ aprepitant brands, Cinvanti and Aponvie, around three years before patent expiry after settling litigation with the originator. Other court cases remain ongoing.